Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Atelectasis II: Pathophysiology01:10

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.

American journal of respiratory and critical care medicine·2026
Same author

Prognostic Significance of Peripheral Blood Monocyte Count Among a National Cohort of Veterans with Pulmonary Fibrosis.

Annals of the American Thoracic Society·2025
Same author

If it's broken, fix it: clinical trials need a paradigm shift.

The European respiratory journal·2025
Same author

Health research in academic health systems: time for a new model.

Health affairs scholar·2024
Same author

Defining the Learning Health Care System: An International Health System Leadership Perspective.

Academic medicine : journal of the Association of American Medical Colleges·2023
Same author

Neighborhood Health and Outcomes in Idiopathic Pulmonary Fibrosis.

Annals of the American Thoracic Society·2023

Related Experiment Video

Updated: Jul 14, 2026

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

Idiopathic pulmonary fibrosis.

Luca Richeldi1, Harold R Collard2, Mark G Jones3

  • 1Unità Operativa Complessa di Pneumologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli, Rome, Italy; National Institute for Health Research Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, University of Southampton, Southampton, UK.

Lancet (London, England)
|April 3, 2017
PubMed
Summary

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease. Recent advances have transformed IPF understanding and management, with two new therapies offering hope for fibrotic lung conditions.

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit
05:56

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit

Published on: September 6, 2024

Related Experiment Videos

Last Updated: Jul 14, 2026

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit
05:56

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit

Published on: September 6, 2024

Area of Science:

  • Pulmonology
  • Fibrotic Lung Diseases
  • Extracellular Matrix Biology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease characterized by destruction of alveolar architecture.
  • This leads to decreased lung compliance, impaired gas exchange, respiratory failure, and mortality.
  • Significant progress in understanding IPF pathogenesis has occurred recently.

Purpose of the Study:

  • To summarize the current understanding of idiopathic pulmonary fibrosis.
  • To review the presentation, pathophysiology, and diagnosis of IPF.
  • To outline available treatment options for IPF patients.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Synthesis of information on IPF pathogenesis and therapeutic strategies.
  • Summary of diagnostic criteria and clinical presentation.

Main Results:

  • Understanding of IPF pathogenesis has rapidly advanced.
  • Two disease-modifying therapies have been approved globally.
  • IPF research provides insights into other progressive fibrotic lung diseases.

Conclusions:

  • Recent breakthroughs have transformed the management of IPF.
  • New therapeutic approaches offer hope for patients with IPF.
  • Advances in IPF serve as a model for treating other fibrotic lung diseases.